Drug safety evaluation of maraviroc for the treatment of HIV infection

Expert Opinion on Drug Safety

Volumn 11, Issue 1, 2012, Pages 161-174

  Wasmuth, Jan Christian ^a   Rockstroh, Jrgen Kurt ^a   Hardy, William David ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV infection; Maraviroc; Treatment; Tropism

Indexed keywords

ABACAVIR; APLAVIROC; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; NEVIRAPINE; OXIDOREDUCTASE INHIBITOR; PLACEBO; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MEDLINE; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINITIS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VIRAL TROPISM;

ANIMALS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; DRUG MONITORING; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; TIME FACTORS; TRIAZOLES;

EID: 84555191719     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.640670     Document Type: Article

References (89)

1. Saag M, Goodrich J, Fatkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009;199:1638-47
2. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-55
3. Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother 2009;63:1087-96
4. Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65(Suppl 1):60-7 (Pubitemid 351366540)
5. Abel S, van der Ryst E, Rosario MC, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):5-18 (Pubitemid 351366533)
6. Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):27-37 (Pubitemid 351366536)
7. Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):38-46 (Pubitemid 351366537)
8. Marviroc (Selzentry®). United States Prescribing Information. Pfizer Inc; New York: 2011
9. Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010;69:51-7
10. Nozza S, Galli L, Visco F, et al. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 2010;24:924-8
11. Melica G, Canestri A, Peytavin G, et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 2010;24:2130-3
12. Tiraboschi JM, Niubo J, Curto J, et al. Maraviroc Concentrations in Cerebrospinal Fluid in HIV-Infected Patients. J Acquir Immune Defic Syndr 2010;Available from: http://www.ncbi. nlm.nih.gov/pubmed/20706127 Last accessed 25 May 2011
13. Yilmaz A, Watson V, Else L, et al. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009;23:2537-40
14. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009;51:546-53
15. Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 2011;203:1484-90
16. Mosier DE. How HIV changes its tropism: evolution and adaptation? Curr Opin HIV AIDS 2009;4:125-30
17. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, et al. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS 2008;22:1425-31
18. Poveda E, Briz V, Quinones-Mateu M, et al. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006;20:1359-67 (Pubitemid 43948242)
19. Rose JD, Rhea AM, Weber J, et al. Current tests to evaluate HIV-1 coreceptor tropism. Curr Opin HIV AIDS 2009;4:136-42
20. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-75 (Pubitemid 46185274)
21. Trofile® DNA (HIV Tropism Test). Available from: http://www. monogramvirology.com/hiv-tests/resistance-testing/tropism/trofile-dna/Last accessed 15 October 2011
22. Gonzalez N, Perez-Olmeda M, Mateos E, et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother 2010;65:2493-501
23. Gonzalez-Serna A, Leal M, Genebat M, et al. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J Clin Microbiol 2010;48:4453-8
24. Raymond S, Delobel P, Mavigner M, et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010;47:126-30
25. Chan SY, Speck RF, Power C, et al. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol 1999;73:2350-8 (Pubitemid 29098140)
26. Jensen MA, Li F-S, van 't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77:13376-88 (Pubitemid 37494331)
27. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007;21:F17-24 (Pubitemid 47329758)
28. Harrigan PR, McGovern R, Dong W, et al. Screening for HIV tropism using population-based V3 genotypic analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1. Antivir Ther 2008;13(Suppl 3):A106
29. Reuter S, Braken P, Jensen B, et al. Maraviroc in treatment-experienced patients with HIV-1 infection-experience from routine clinical practice. Eur J Med Res 2010;15:231-7
30. Daumer M, Kaiser R, Klein R, et al. Inferring viral tropism from genotype with massively parallel sequencing: qualitative and quantitative analysis. Antivir Ther 2008;13(Suppl 3):A101
31. Saliou A, Delobel P, Dubois M, et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011;55:2831-6
32. Svicher V, Balestra E, Cento V, et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res 2011;90:42-53
33. Swenson L, Dong W, Mo T, et al. Quantification of HIV Tropism by "deep" sequencing shows abroad distribution of prevalence of X4 variants in clinicalsamples that is associated with virological outcome abstract 680. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada
34. Vandekerckhove L, Wensing A, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11:394-407
35. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; Washington, D.C.: 2011. p. 1-166
36. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
37. Hardy WD, Gulick RM, Mayer H, et al. Two-Year Safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-Tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;55:558-64
38. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
39. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78 (Pubitemid 46541620)
40. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
41. Lanzafame M, Lattuada E, Vento S. Maraviroc and CD4+ cell count recovery in patients with virologic suppression and blunted CD4+ cell response. AIDS 2009;23:869
42. Stepanyuk O, Chiang TS, Dever LL, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009;23:1911-13
43. Wilkin T, Lalama C, Tenorio A, et al. Maraviroc intensification for SUboptimal CD4+ cell response despite sustained virologic suppression: ACTG 5256 abstract 285. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010); 16-19 February 2010; San Francisco, CA
44. Hunt P, Shulman N, Hayes T, et al. Immunomodulatory Effects of MVC intensification in HIV-infected individuals with incomplete CD4+ T cell recovery during suppressive ART abstract 153LB. 18th Conference on Retroviruses & Opportunistic Infections (CROI 2011); 27 February-2 March 2011; Boston, MA
45. Rusconi S, Vitiello P, Adorni F, et al. Maraviroc intensification for HIV-1-positive immunological nonresponders(INRs) despite virological suppression during HAART abstract O44. 10th International Congress on Drug Therapy in HIV Infection; 7 November 2010; Glasgow, UK
46. Funderburg N, Kalinowska M, Eason J, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4 + cell rises in HIV-infected patients. PLoS One 2010;5:e13188
47. Wilkin T, Lalama C, Tenorio A, et al. Effect of Adding and Removing MVC on Immune Activation in HIV+ Patients on Suppressive ART: Results from ACTG A5256 abstract 574. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA
48. Hilldorfer B, Lalama C, McKinnon J, et al. Effects of maraviroc (MVC) intensification on residual low-level viremia in patients on suppressive antiretroviral therapy (ART): results from ACTG 5256 abstract MOPE275. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy
49. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2 (Pubitemid 43093663)
50. Randell P, Jackson A, Taylor J, et al. Maraviroc has a benign impact on glucose and lipidhomeostasis after 2 weeks in HIV-negative malevolunteers abstract LBPE9.2/8. 12th European AIDS Conference; 12-14 November 2009; Cologne, Germany
51. Heera J, Ive P, Botes M, et al. The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results abstract TUAB103. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa
52. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005;42:854-62 (Pubitemid 41401123)
53. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-65 (Pubitemid 351358363)
54. Abel S, Davis JD, Ridgway CE, et al. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antivir Ther (Lond) 2009;14:831-7
55. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12 (Pubitemid 47047471)
56. Tsibris AMN, Paredes R, Chadburn A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis 2009;48:642-9
57. Walmsley S, Campo R, Goodrich J, et al. Low risk of malignancy with maraviroc in treatment-experienced (TE) and treatment-navie (TN) patients across the maraviroc clinical development program abstract TUPE0157. XVIII International AIDS Conference; 18-23 July 2010; Vienna, Austria
58. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40 (Pubitemid 43139642)
59. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-5 (Pubitemid 351263445)
60. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008;198:500-7
61. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009;4:131-5
62. Nozza S, Galli L, Bigoloni A, et al. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr 2011;56:e113-15
63. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192:466-74 (Pubitemid 41023125)
64. Poveda E, Briz V, de Mendoza C, et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007;79:1040-6 (Pubitemid 47015401)
65. Heera J, Saag M, Ive P, et al. Virological correlates associated with treatment failure atweek 48 in the phase 3 study of Maraviroc in treatment-naïvepatients abstract 40LB. 15th Conference on Retroviruses and Opportunistic Infections; 3-5 February 2008; Boston, MA
66. Nelson M, on behalf of the MERIT study team. 96-week resultsof the MERIT trial abstract MOPEBO4O. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa
67. Portsmouth S, Craig C, Mills A, et al. 48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + TV/r in treatment-naïve (TN) patients infected with CCR5-tropic HIV abstract TUAB0103. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy
68. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009;9:37-42
69. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26
70. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther (Lond) 2006;11:729-40 (Pubitemid 44497168)
71. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13 (Pubitemid 350301936)
72. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009;11:30-8
73. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006;29:865-74 (Pubitemid 44511587)
74. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59
75. Wilkin TJ, Ribaudo HR, Tenorio AR, et al. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials 2010;11:351-8
76. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77 (Pubitemid 26272077)
77. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3 (Pubitemid 26375409)
78. Neff CP, Kurisu T, Ndolo T, et al. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS ONE 2011;6:e20209
79. Maraviroc in Rheumatoid Arthritis-ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00427934 Last accessed 13 October 2011
80. ClinicalStudyResults.org-Drug Details. Available from: http://www. clinicalstudyresults.org/drugdetails/? study-name=A4001056&sort=c. company-name&page=1&drug-id=9756 Last accessed 13 October 2011
81. Hellier S, Frodsham AJ, Hennig BJW, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003;38:1468-76 (Pubitemid 37466973)
82. Thio CL, Astemborski J, Bashirova A, et al. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol 2007;81:441-5 (Pubitemid 46067870)
83. Braunersreuther V, Steffens S, Arnaud C, et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 2008;28:1090-6
84. Wheeler J, McHale M, Jackson V, et al. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir Ther (Lond) 2007;12:233-45 (Pubitemid 46569908)
85. Reale M, Iarlori C, Feliciani C, et al. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 2008;14:147-59 (Pubitemid 352040032)
86. Thio CL, Astemborski J, Thomas R, et al. Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. J Immunol 2008;181:7944-7
87. Vincent T, Portales P, Baillat V, et al. T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists. J Acquir Immune Defic Syndr 2005;38:305-9 (Pubitemid 40333496)
88. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-71
89. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-28 (Pubitemid 46551222)